| 0.2581 0.004 (1.45%) | 04-14 09:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.4 | 1-year : | 0.53 |
| Resists | First : | 0.34 | Second : | 0.46 |
| Pivot price | 0.22  |
|||
| Supports | First : | 0.16 | Second : | 0.13 |
| MAs | MA(5) : | 0.23 |
MA(20) : | 0.25 |
| MA(100) : | 0.88 |
MA(250) : | 1.31 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 35.5 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 3.39 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OTLK ] has closed below upper band by 26.1%. Bollinger Bands are 80.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.27 - 0.27 | 0.27 - 0.27 |
| Low: | 0.22 - 0.22 | 0.22 - 0.22 |
| Close: | 0.25 - 0.25 | 0.25 - 0.26 |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Wed, 08 Apr 2026
Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Sahm
Tue, 07 Apr 2026
Outlook Therapeutics Announces Formal Dispute Resolution - GlobeNewswire
Wed, 01 Apr 2026
OTLK SEC Filings - Outlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 25 Mar 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering - GlobeNewswire
Tue, 24 Mar 2026
20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan
Mon, 23 Mar 2026
Outlook Therapeutics launches public stock offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 7.089e+007 (%) |
| Held by Institutions | 14.6 (%) |
| Shares Short | 4,500 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.882e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 1 % |
| Return on Assets (ttm) | 116.3 % |
| Return on Equity (ttm) | -209.1 % |
| Qtrly Rev. Growth | 205700 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.50667e+008 |
| Qtrly Earnings Growth | -2.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.03 |
| Dividend | 0 |
| Forward Dividend | 3.18e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|